公开(公告)号：US20230187042A1

公开(公告)日：2023-06-15

申请号：US18050353

申请日：2022-10-27

申请人： Iovance Biotherapeutics, Inc.

发明人： Frederick G. Vogt ,  Binh Lam ,  Jennifer Chang ,  Ramona Repaczki-Jones

IPC分类号： G16H20/00 ,  A61K35/12 ,  C12N5/09 ,  G06Q10/0832 ,  G16H10/60 ,  G16H80/00

CPC分类号： G16H20/00 ,  A61K35/12 ,  C12N5/0693 ,  G06Q10/0832 ,  G16H10/60 ,  G16H80/00

摘要： A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.

公开(公告)号：US20240207318A1

公开(公告)日：2024-06-27

申请号：US18555513

申请日：2022-04-19

申请人： Yongliang ZHANG ,  Iovance Biotherapeutics, Inc.

发明人： Rafael Cubas ,  Frederick G. Vogt ,  Yongliang Zhang

IPC分类号： A61K35/17 ,  A61K38/20 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/86

CPC分类号： A61K35/17 ,  A61K38/2013 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464411 ,  A61P35/00 ,  C07K16/2827 ,  C07K16/30 ,  C12N5/0638 ,  C12N15/86 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/55 ,  C12N2740/10043 ,  C12N2740/15043

摘要： The present invention provides compositions comprising chimeric receptors, including chimeric costimulatory receptors (CCRs), and/or chemokine receptors, methods for preparing CCRs and/or chemokine receptors, and therapeutic populations of tumor infiltrating lymphocytes, marrow infiltrating lymphocytes, and peripheral blood lymphocytes expressing CCRs and/or chemokine receptors with increased therapeutic performance and other advantages for the treatment of cancers, including solid tumor cancers.

公开(公告)号：US20240299540A1

公开(公告)日：2024-09-12

申请号：US18262843

申请日：2022-02-07

申请人： Iovance Biotherapeutics, Inc.

发明人： Frederick G. Vogt ,  Cecile Chartier-Courtaud

IPC分类号： A61K39/00 ,  A61K39/395 ,  A61N1/32 ,  C12N5/0783

CPC分类号： A61K39/4611 ,  A61K39/3955 ,  A61K39/464499 ,  A61N1/327 ,  C12N5/0636 ,  A61K2239/38 ,  A61K2239/39 ,  C12N2501/2302 ,  C12N2502/30

摘要： The present invention provides methods for expanding TILs and producing therapeutic populations of TILs. According to exemplary embodiments, at least a portion of the therapeutic population of TILs are gene-edited to enhance their therapeutic effect. According to further embodiments, methods for gene-editing TILs include intratumoral delivery of expression vectors for immune checkpoint inhibitors using an electroporation system prior to harvesting the tumor for TIL production. According to yet further embodiments, an adjuvant therapy for cancer includes delivery of expression vectors for immune checkpoint inhibitors before, after or before and after infusion of TILs for treating cancer.